US 12129262
CDK inhibitors and their use as pharmaceuticals
granted A61PA61P35/00
Quick answer
US patent 12129262 (CDK inhibitors and their use as pharmaceuticals) held by Prelude Therapeutics, Incorporated expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Prelude Therapeutics, Incorporated
- Grant date
- Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 29
- CPC classes
- A61P, A61P35/00